Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
NCT ID: NCT00143455
Last Updated: 2010-02-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
485 participants
INTERVENTIONAL
2002-06-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer
NCT00349492
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
NCT00045162
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00072527
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
NCT00043927
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00003606
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
Etoposide + cisplatin
etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
A
Irinotecan + cisplatin
irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etoposide + cisplatin
etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
Irinotecan + cisplatin
irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WHO performance status : 0, 1
Exclusion Criteria
* No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Wels, , Austria
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Liège, , Belgium
Pfizer Investigational Site
Brno-Bohunice, , Czechia
Pfizer Investigational Site
Olomouc, , Czechia
Pfizer Investigational Site
Ostrava - Poruba, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Ústí nad Labem, , Czechia
Pfizer Investigational Site
Alexandria, , Egypt
Pfizer Investigational Site
Cairo, , Egypt
Pfizer Investigational Site
Amiens, , France
Pfizer Investigational Site
Bobigny, , France
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Brest, , France
Pfizer Investigational Site
Caen, , France
Pfizer Investigational Site
Limoges, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Meaux, , France
Pfizer Investigational Site
Mulhouse, , France
Pfizer Investigational Site
Pierre-Bénite, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Rouen, , France
Pfizer Investigational Site
Saint-Brieuc, , France
Pfizer Investigational Site
Saint-Etienne, , France
Pfizer Investigational Site
Saint-Pierre, , France
Pfizer Investigational Site
Villefranche-sur-Saône, , France
Pfizer Investigational Site
Villejuif, , France
Pfizer Investigational Site
Bad Berka, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bovenden-Lenglern, , Germany
Pfizer Investigational Site
Ebensfeld, , Germany
Pfizer Investigational Site
Gauting, , Germany
Pfizer Investigational Site
Göttingen, , Germany
Pfizer Investigational Site
Großhansdorf, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Heidelberg, , Germany
Pfizer Investigational Site
Hemer, , Germany
Pfizer Investigational Site
Löwenstein, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Groningen, , Netherlands
Pfizer Investigational Site
Maastricht, , Netherlands
Pfizer Investigational Site
Nieuwegein, , Netherlands
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Otwock, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow 115 478, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Barcelona, BARCELONA, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Aarau, , Switzerland
Pfizer Investigational Site
Basel, , Switzerland
Pfizer Investigational Site
Bellinzona, , Switzerland
Pfizer Investigational Site
Bern, , Switzerland
Pfizer Investigational Site
Ch-4101 Bruderholz, , Switzerland
Pfizer Investigational Site
Thun, , Switzerland
Pfizer Investigational Site
Taichung, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taipei, , Taiwan
Pfizer Investigational Site
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XRP4174D-3001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.